News Novartis files CAR-T in Europe in broader use than Gilead ri... Swiss pharma chasing EU licence in NHL and ALL indications
News Novartis files CAR-T in lymphoma, sets up rivalry with Gilea... Swiss pharma to compete with Gilead in non-Hodgkin lymphoma
News Gilead gains CAR-T approval, undercuts rival's headline pric... Cancer cell therapy approved for aggressive blood cancer
News AbiVax claims progress towards HIV cure French biotech to step up clinical development of ABX464.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
